Regeneron Commences Clinical Trial of Efficacy and Safety of VEGF Trap-Eye in Patients With Choroidal Neovascularisation (CNV) of the Retina
January 20, 2011
Submit Comments
Regeneron and Bayer HealthCare recently announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute (SERI) to investigate the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia. The trial has started in Japan and other Asian countries, including China, Korea, Singapore, and Taiwan.
Comments
Jump down to form below to submit your own comments
